Navigation Links
Tengion Provides Update on Neo-Urinary Conduit Clinical Trial
Date:6/13/2011

Augment; (ii) expectations regarding the initial clinical trial of the Neo-Urinary Conduit and (iii) expectations regarding planned preclinical studies of the Neo-Kidney Augment. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company's Neo-Urinary Conduit clinical trial will not be placed on clinical hold by the Food and Drug Administration, or FDA; (ii) patients enrolled in the Company's Neo-Urinary Conduit clinical trial will not experience additional adverse events, which could delay clinical trials or cause the Company to terminate the development of the Neo-Urinary Conduit; (iii) the Company will be able to successfully enroll patients in its clinical trials, including its initial clinical trial for the Neo-Urinary Conduit; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (v) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candidates; and (vi) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trial and (vii) the Company will be able to obtain the capital it needs to develop its product candidates and continue its operations.  For additional factors which could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.  The forward looking statements in this release are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this rele
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Announces FDA Orphan-Drug Designation for Neo-Urinary Conduit
2. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
3. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
4. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
5. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
6. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
7. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
8. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
9. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
10. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... March 27, 2015 Across the global healthcare ... challenges in clinical development, market education, and regulatory compliance. ... Medical Affairs function is expected to increase in prominence ... According to research by benchmarking firm, Best ... group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... , March 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced the issuance of an aggregate ... the Company and an aggregate of 120,500 stock options ... options will vest over three years and will be ... exercise price of $1.40 per stock option. ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Covalon Announces Issuance of Stock Options 2
... LAIYANG, China , June 4 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, ... its principal operations in China , today,announced that the Company has ... , , ... anticipates that its common stock will begin trading on the NASDAQ,Global Market ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ), a specialty ... Chief Executive Officer A.J. Kazimi will present a corporate overview at ... Eastern Time on Wednesday, June 23, 2010 . , ... The presentation will be simultaneously webcast and can ...
Cached Medicine Technology:Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 3Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010 2
(Date:3/30/2015)... March 30, 2015 Tel-Aviv – March ... prescription eyewear, announced the closing of $12.5 million in ... of the Viola Group. The funding will further GlassesUSA's ... leading player in the growing global market of online ... in 2009 by CEO Daniel Rothman, COO Eldad Rothman, ...
(Date:3/30/2015)... Dr. Shahdad Arami is now offering ... $200 off their Invisalign treatment. Many people crave straighter ... mouthful of metal. Invisalign offers an alternative. According to ... effective for straightening teeth but has no aesthetic value ... appearance. The Invisalign system allows both teenagers and adults ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
(Date:3/30/2015)... GenSight ®, provider of an ... leader in The Forrester Wave™: Strategic Planning For The ... independent report positions GenSight as a leader and gave ... 5) for the analytics, corporate strategy, assessment, direction and ... position in the Leaders category. , According to the ...
(Date:3/30/2015)... In an email sent to ECOBOND® LBP, ... TN Community Development Department, announced: “I specifically named Ecobond ... work”. , ECOBOND® LBP, patented lead ... and surpasses other lead paint products because it is ... treats lead dust and lead in paint. While lead ...
Breaking Medicine News(10 mins):Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:ECOBOND® Selected to Protect School Children in Oak Ridge Tennessee in Lead Based Paint Remediation Project. 2
... , VIRGINIA BEACH, Va., Sept. 10 ... implant of a CardioGraft(TM) allograft cardiac patch product with MatrACELL(TM)( ... in Kansas City, Mo by Gary K. Lofland, ... Mercy Hospital in Kansas City, Mo, The Joseph Boon Gregg/Missouri ...
... LEXINGTON, Ky., Sept. 10 VirtualHealth Technologies, Inc. (OTC Bulletin ... records and connectivity for web-based healthcare solutions, announced today an ... Secure Document Courier and Storage technology (Cifra(TM)) to the healthcare ... will have preferred rights to market Cifra directly to end ...
... , , WASHINGTON, Sept. 10 ... and other leading medical experts today urged Americans to be vigilant ... threat to Americans, health each and every year. , , ... and Americans should begin to get vaccinated now. Seasonal vaccine supply ...
... Researchers at UC Santa Barbara have developed a new way ... to a non-harmful laser. Their results are published in a ... the American Chemical Society. "This entirely novel tool will ... with temporal and spatial control over when a gene is ...
... person,s social life could have an even greater impact than ... growing evidence that being a member of a social group ... and even the common cold. New research by ... of social groups has a positive impact on health and ...
... LOS ANGELES, Sept. 10 Award-winning actresses Edie Falco and ... public service campaign to educate cancer patients and their loved ones ... importance of learning how to manage one,s risk. , , ... http://www.prnewswire.com/mnr/amgen/39907/ , , (Photo: ...
Cached Medicine News:Health News:LifeNet Health and Children's Mercy Hospital Announce First Implant With MatrACELL(TM) Technology 2Health News:LifeNet Health and Children's Mercy Hospital Announce First Implant With MatrACELL(TM) Technology 3Health News:VirtualHealth Technologies Announces Secure eHealth Agreement With DRM Security to Market Secure Document Courier and Storage Platform 2Health News:VirtualHealth Technologies Announces Secure eHealth Agreement With DRM Security to Market Secure Document Courier and Storage Platform 3Health News:VirtualHealth Technologies Announces Secure eHealth Agreement With DRM Security to Market Secure Document Courier and Storage Platform 4Health News:VirtualHealth Technologies Announces Secure eHealth Agreement With DRM Security to Market Secure Document Courier and Storage Platform 5Health News:Americans Urged To Get Seasonal Influenza Vaccine Early 2Health News:Americans Urged To Get Seasonal Influenza Vaccine Early 3Health News:Americans Urged To Get Seasonal Influenza Vaccine Early 4Health News:Americans Urged To Get Seasonal Influenza Vaccine Early 5Health News:Americans Urged To Get Seasonal Influenza Vaccine Early 6Health News:UCSB researchers develop drug delivery system using nanoparticles and lasers 2Health News:Groups are key to good health 2Health News:Groups are key to good health 3Health News:Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment 2Health News:Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment 3
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Medicine Products: